ClinicalTrials.gg
RecruitingNCT05862831Updated May 17, 2023

Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors

A Phase 1/2 interventional study of PM1003 Injection in Advanced Solid Tumors, sponsored by Biotheus Inc.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 8 months after the study started (first participant enrolled Sep 2021, registered May 2023).
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
285
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a single-arm, open-lable, multicenter phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PM1003 in the treatment of advanced solid tumors.

Read the detailed description

PM1003 is a Bispecific Antibody Targeting PD-L1 and 4-1BB.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • PD-L1, 4-1BB
03

In context

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in clinical study; fully understand the study and sign voluntarily; willing to follow and able to complete all test procedures;
  2. Male or female aged 18 to 75 years;
  3. Subjects with malignant tumor confirmed by histology or cytology;
  4. Adequate organ function;
  5. score was 0-1.
  6. Pre-menopausal female subjects with negative blood pregnancy results within 7 days prior to the study treatment, and agree to abstain from sex or use medically approved effective measures for 6 months from the date of signing the informed consent form to the end of the last medication;
  7. Male subjects are agree to abstain from sex or use medically approved effective contraceptive methods for 6 months from the date of signing the informed consent form to the end of the last medication, and do not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic to macromolecular protein drugs, severe allergy to drugs or known allergy to any component of the drug in this study;
  2. Treatment with any 4-1BB monoclonal antibody or 4-1BB-containing dual antibody immune co-stimulatory molecule agonist;
  3. Current active infection requiring intravenous anti-infective therapy;
  4. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
  5. Known history of alcohol abuse, psychotropic drug abuse or drug abuse;
  6. History of neurological or psychiatric disorders, such as epilepsy, dementia, schizophrenia, etc.;
  7. Anticipated need for any other form of antineoplastic drug treatment during the trial;
  8. Women who are pregnant or breastfeeding;
  9. Other conditions lead to inappropriate to participate in this study as judged by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    PM1003

    PM1003 0.02mg/kg-10mg/kg

    Biological: PM1003 Injection

Interventions

  • BiologicalPM1003 Injection

    Subjects will receive PM1003 by intravenous administration.

06

What researchers measure

Primary outcomes

  1. Dose Limited Toxicity(DLT)

    Occurrence of DLT after receiving PM1003 injection

    Time frame: up to 21 days

  2. Assess the incidence and severity of treatment-related adverse events

    The incidence and severity of treatment-emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) graded according to NCI-CTCAE v5.0

    Time frame: Up to 30 days after last treatment

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Sep 2025, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
May 17, 2023
StartActual
Sep 7, 2021
Primary completionEst.
Sep 7, 2025
CompletionEst.
Nov 15, 2025
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05862831
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
May 17, 2023
Start date
Sep 7, 2021
Primary completion
Sep 7, 2025 (estimated)
Completion
Nov 15, 2025 (estimated)
Last update
May 17, 2023

Study contacts

Jie Zhang
Contact
zhang.jie@biotheus.com
+86 18221509791
Ye Guo
principal investigator · Shanghai Orient Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion